Aqilion announces final outcome of rights issue
The Board of Directors of Aqilion AB (publ) ("Aqilion" or the "Company") today announces the outcome of the Company's rights issue of shares (the "Rights Issue") resolved by the Board of Directors on 11 February 2025, based on the authorization granted by the Annual General Meeting on 10 June 2024 (the "Rights Issue"). The subscription summary shows that a total of 854,792 shares, corresponding to approximately 41.53 percent of the Rights Issue, were subscribed for with and without subscription rights. Through the Rights Issue, Aqilion will thus receive approximately SEK 11.1 million before issuance costs.
The subscription period for the Rights Issue ended on March 26, 2025 and the summary shows that 820,257 shares, corresponding to 39.86 percent, were subscribed for with subscription rights. In addition, the Company received applications for subscription of an additional 34,535 shares without subscription rights, corresponding to 1.67 percent. The Rights Issue is thus subscribed to a total of 41.53 percent and Aqilion will thus receive approximately SEK 11.1 million before deduction of issuance costs.
All subscribers without preferential rights have received full allotment. Notice of allotment to those who have subscribed for shares without subscription rights has been distributed on 27 March 2025 together with a settlement note. Nominee-registered shareholders will receive notification of allotment in accordance with the respective nominee's procedures. Allotment of shares subscribed for without subscription rights has been carried out in accordance with the principles set out in the Information Memorandum that the Company sent to existing shareholders on 21 February 2025.
Number of shares and share capital
Following registration of the Rights Issue with the Swedish Companies Registration Office, Aqilion's share capital will increase by SEK 427,396.00, from SEK 3,420,083.00 to a total of SEK 3,857,479.00. The number of shares in the Company will increase by 854,792 shares, from 6,860,166 to a total of 7,714,958 shares.
Counsellor
Redeye AB is acting as financial advisor, HWF Advokater AB is acting as legal advisor and Nordic Issuing AB is acting as issuing agent to Aqilion in connection with the rights issue.
For further information, please contact:
Sarah Fredriksson, vd, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com
Gustaf Albèrt, CFO, AQILION AB, + 46 (0)709 168 302, gustaf.albert@aqilion.com
About Aqilion
Aqilion is a biotechnology company focused on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immunological reactions such as autoimmune diseases.
We identify innovative ideas that have the potential to become new drugs and refine them into commercially interesting projects. The ideas we choose are based on a solid scientific foundation where we can clearly understand the underlying biology, clinical relevance and patient benefit with reasonable assumptions.
The company is primarily active in the early phases of drug development, from the idea stage to proof-of-concept in clinical studies. Aqilion runs its development programs in a partially virtual organization in close collaboration with selected partners with special cutting-edge knowledge in drug development.
AQILION AB (publ) is a Swedish public limited liability company headquartered in Helsingborg, Sweden. www.aqilion.com
